FDA rejection raises serious questions for Momenta

The fallout over the FDA's rejection of Momenta's generic version of Lovenox--a rare setback for any developer--is continuing to dent the drug developer's reputation. Analysts have zeroed in on the implications the rejection has for Momenta's whole approach to development. As Cowen & Co. analyst Eric Schmidt noted, "We expect investors to be skeptical around Momenta's entire technology platform, pipeline and complex generic strategy." Ouch.

- read the report from The Wall Street Journal
- take a look at yesterday's release on the rejection

Related Articles:
Momenta shares tumble after FDA rejection. Report
Momenta sees delay in generic Lovenox development. Report
Sanofi loses Lovenox patent protection. Report
Lovenox reduces cardio risks but can cause bleeding. Report
Sandoz takes big stake in Momenta. Report
Lovenox reduces cardio risks but can cause bleeding. Report